Body Mass Index and the Success of Helicobacter-pylori Eradication Therapy

Background: Helicobacter pylorus (H. pylori) is a Gram-negative spiral bacterium related to several gastric and extra-gastric complications. The effects of H. pylori infection on cardiometabolic diseases such as dyslipidemia, diabetes, and metabolic syndrome have been investigated. The present paper aims to assess the effects of body mass index on the success of Helicobacter pylori eradication therapy for the first time. Methods and Materials: This study included 198 patients with H. pylori infection. The patients underwent H. pylori eradication using clarithromycin (500 mg, twice daily), pantoprazole (40 mg, twice daily), amoxicillin (500 mg, three times daily), and bismuth substrate (120 mg, twice daily) for 14 days. After that, the success of eradication was assessed through stool antigen within a month following the treatment. The association of eradication success with age, gender, and Body Mass Index (BMI) was evaluated. Results: H. pylori infection was eradicated in 76.3% (P 0.001) of the patients following the treatment. The rate of response to anti-H. pylori remedy was affected by age (P= 0.29). But it was not affected by gender (P= 0.81) and BMI (P= 0.60). Conclusion: Based on the study findings, the patients’ response to the H. pylori eradication was not affected by age, gender, and BMI.